Image Description

INVESTORS
& MEDIA

circle

INVESTOR OVERVIEW

There are currently no events to display.

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. CytokineticMore >>

ANNUAL REPORT

CORPORATE PRESENTATION

CYTOKINETICS FACT SHEETS

fact1

Company

03/15/17
( FY )
ALS

ALS

03/15/17
( FY )
SMA

SMA

03/15/17
( FY )

NEWS

Date Title and Summary
Toggle Summary Cytokinetics Announces $33 Million Financing
Cytokinetics Announces $33 Million Financing South San Francisco, CA, January 18, 2006 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced it has obtained commitments to purchase $33.0 million of its common stock in a registered direct offering. Under the terms of the Stock Purchase Agreement,
Toggle Summary Cytokinetics to Release Fourth Quarter and Full Year 2005 Results on January 31, 2006
Cytokinetics to Release Fourth Quarter and Full Year 2005 Results on January 31, 2006 South San Francisco, CA, January 24, 2006 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it will report fourth quarter and year end 2005 financial results on Tuesday, January 31, 2006 at 4:00
Toggle Summary Cytokinetics, Incorporated Reports Fourth Quarter and Year End 2005 Financial Results
SOUTH SAN FRANCISCO, CA, January 31, 2006 - Cytokinetics, Incorporated (Nasdaq: CYTK), reported revenues from research and development collaborations of $2.1 million for the fourth quarter of 2005. Net loss for the fourth quarter of 2005 was $11.1 million or $0.38 per share.
Toggle Summary Cytokinetics to Present at the BIO CEO & Investor Conference 2006
Cytokinetics to Present at the BIO CEO & Investor Conference 2006 South San Francisco, CA, February 8, 2006 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that James H. Sabry, M.D., Ph.D., President and Chief Executive Officer, is scheduled to present a corporate update at the BIO CEO

EVENTS

There are currently no events to display.